These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 26142669)
1. Vaccines for tumor prevention: a pipe dream? Forni G J Infect Dev Ctries; 2015 Jul; 9(6):600-8. PubMed ID: 26142669 [TBL] [Abstract][Full Text] [Related]
2. Therapeutic cancer vaccines: a long and winding road to success. Baxevanis CN; Papamichail M; Perez SA Expert Rev Vaccines; 2014 Jan; 13(1):131-44. PubMed ID: 24224539 [TBL] [Abstract][Full Text] [Related]
3. Breast cancer vaccines: promise for the future or pipe dream? Mittendorf EA; Peoples GE; Singletary SE Cancer; 2007 Oct; 110(8):1677-86. PubMed ID: 17763371 [TBL] [Abstract][Full Text] [Related]
4. Evolution of animal models in cancer vaccine development. Wei WZ; Jones RF; Juhasz C; Gibson H; Veenstra J Vaccine; 2015 Dec; 33(51):7401-7407. PubMed ID: 26241945 [TBL] [Abstract][Full Text] [Related]
5. Personalized cancer neoantigen vaccines come of age. Chu Y; Liu Q; Wei J; Liu B Theranostics; 2018; 8(15):4238-4246. PubMed ID: 30128050 [TBL] [Abstract][Full Text] [Related]
6. Prevention of metastases with a Mage-b DNA vaccine in a mouse breast tumor model: potential for breast cancer therapy. Sypniewska RK; Hoflack L; Tarango M; Gauntt S; Leal BZ; Reddick RL; Gravekamp C Breast Cancer Res Treat; 2005 May; 91(1):19-28. PubMed ID: 15868428 [TBL] [Abstract][Full Text] [Related]
7. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. Berzofsky JA; Terabe M; Oh S; Belyakov IM; Ahlers JD; Janik JE; Morris JC J Clin Invest; 2004 Jun; 113(11):1515-25. PubMed ID: 15173875 [TBL] [Abstract][Full Text] [Related]
8. Cancer vaccines: harnessing the potential of anti-tumor immunity. Suckow MA Vet J; 2013 Oct; 198(1):28-33. PubMed ID: 23850019 [TBL] [Abstract][Full Text] [Related]
10. Design of universal cancer vaccines using natural tumor vessel-specific antigens (SANTAVAC). Lokhov PG; Balashova EE Hum Vaccin Immunother; 2015; 11(3):689-98. PubMed ID: 25714389 [TBL] [Abstract][Full Text] [Related]
11. Universal cancer vaccine: an update on the design of cancer vaccines generated from endothelial cells. Lokhov PG; Balashova EE Hum Vaccin Immunother; 2013 Jul; 9(7):1549-52. PubMed ID: 23571178 [TBL] [Abstract][Full Text] [Related]
12. Cancer vaccines: an update with special focus on ganglioside antigens. Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591 [TBL] [Abstract][Full Text] [Related]
13. Challenges facing the development of cancer vaccines. Fishman M Methods Mol Biol; 2014; 1139():543-53. PubMed ID: 24619703 [TBL] [Abstract][Full Text] [Related]
14. Tumor vaccine: current trends in antigen specific immunotherapy. Baral R Indian J Exp Biol; 2005 May; 43(5):389-406. PubMed ID: 15900903 [TBL] [Abstract][Full Text] [Related]
15. Clinical development of MVA-based therapeutic cancer vaccines. Acres B; Bonnefoy JY Expert Rev Vaccines; 2008 Sep; 7(7):889-93. PubMed ID: 18767940 [TBL] [Abstract][Full Text] [Related]
16. Termination of systemic immunity in the presence of intraocular tumors: influence of ocular immune privilege on tumor vaccines. Chen PW; Ksander BR Curr Eye Res; 2006 Jan; 31(1):43-55. PubMed ID: 16421019 [TBL] [Abstract][Full Text] [Related]
17. Cancer vaccines: between the idea and the reality. Finn OJ Nat Rev Immunol; 2003 Aug; 3(8):630-41. PubMed ID: 12974478 [TBL] [Abstract][Full Text] [Related]